Loading market dashboard
ProQR Therapeutics N.V.
PRQRHealthcareNASDAQNL
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalysts Continued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI Advisory Board Ended Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027 LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the nomination of Lykke Hinsch Gylvin, MD, EMBA, Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim, to its Board of Directors.
ProQR Therapeutics (NASDAQ: PRQR) outlined multiple pipeline updates and development priorities during its virtual investor and analyst event, highlighting upcoming clinical readouts for its lead RNA editing program AX-0810, a next-generation follow-on candidate (AX-0811), and the addition of two programs, AX-0422 for Hurler syndrome and AX-2911 for metabolic dysfunction-associated steatohepatitis (MASH). AX-0810: Phase I target engagement
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today highlighted key updates from its virtual Investor and Analyst event hosted today.
ProQR and Ginkgo Bioworks to collaborate on autonomous lab high throughput data generation to support ProQR's AI-enabled drug discovery for Axiomer™ ProQR establishes AI Advisory Board with leaders from industry and academia ProQR's first AI-discovered Development Candidate expected to enter the clinic in 2026 LEIDEN, Netherlands & CAMBRIDGE, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
ProQR Therapeutics N.V. (PRQR) Presents at The Citizens Life Sciences Conference 2026 Transcript
ProQR (PRQR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.1 per share a year ago.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the year ended December 31, 2025, and provided a business update.
